picolinic acid has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 1 studies
picolinic acid: iron-chelating agent that inhibits DNA synthesis; may interfere with iron-dependent production of stable free organic radical which is essential for ribonucleotide reductase formation of deoxyribonucleotides; RN given refers to parent cpd; structure in Merck Index, 9th ed, #7206
picolinic acid : A pyridinemonocarboxylic acid in which the carboxy group is located at position 2. It is an intermediate in the metabolism of tryptophan.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In human chronic myelogenous leukemia cells, K562, which are relatively resistant to various inducers of apoptosis, the apoptosis was induced by picolinic acid and dipicolinic acid in about 50% of the cells 5-10 mM via the caspase pathway, but was not at 1 mM." | 1.31 | Apoptosis induced by niacin-related compounds in K562 cells but not in normal human lymphocytes. ( Fujita, H; Ogata, S; Okumura, K; Shibata, K; Taguchi, H; Takeuchi, M, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ogata, S | 1 |
| Takeuchi, M | 1 |
| Fujita, H | 1 |
| Shibata, K | 1 |
| Okumura, K | 1 |
| Taguchi, H | 1 |
1 other study available for picolinic acid and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Apoptosis induced by niacin-related compounds in K562 cells but not in normal human lymphocytes.
Topics: Antineoplastic Agents; Apoptosis; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positi | 2000 |